Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients with Metabolic Syndrome
2007-003130-41Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olmesartan in hypertension (HTN) and cardiometabolic risk (CMR) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in hs-CRP after 6 weeks. Started Apr 2008; status: completed.
02
Drugs
olmesartan
03
Conditions
hypertension (HTN)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2007-003130-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003130-41.